Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 14/20 | 0.82 |
| ▸ | TP53 | P04637 | 4/20 | 0.82 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.82 |
| ▸ | POLB | P06746 | 3/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CTSD | P07339 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12963171 | 0.89 | MAPT (0.82) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL1074520 | 0.87 | TP53 (0.80) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL12963179 | 0.86 | MAPT (0.73) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL16602337 | 0.85 | SMN1; SMN2 (0.75) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL12980388 | 0.84 | MAPT (0.65) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL12963203 | 0.83 | MAPT (0.83) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL12963198 | 0.82 | SMN1; SMN2 (0.70) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL16602336 | 0.82 | MAPT (0.74) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL12963447 | 0.82 | MMP2 (0.70) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL16602333 | 0.82 | HPGD (0.69) | MAPTTP53RXFP1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150852-A1 | TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-8993604-B2 | Treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2015-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150852-A1 | TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | HAVCR2, TTPA, CHIA | MAPT 118/4885TP53 2739/4885RXFP1 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.